The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive metformin (defined as rescue medication) added onto their blinded study medication
Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
Tablets, Oral, 500-2500 mg, as needed (12 months LT)
Belgrano, Buenos Aires, Argentina
Buenos Aires, Buenos Aires, Argentina
Chacabuco, Buenos Aires, Argentina
Ciudad Auton., Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Morón, Buenos Aires, Argentina
Mendoza, Mendoza Province, Argentina
Rosario, Santa Fe Province, Argentina
Lanus Este, Tucumán Province, Argentina
Buenos Aires, Argentina